Protein kinases controlling PCNA and p53 expression in human ovarian cells

Sirotkin, Alexander V.; Ovcharenko, Dmitriy; Benco, Andrej; Mlyncek, M

doi:10.1007/s10142-008-0102-y

Cited by 12 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genome-wide selected blockade of PKs by siRNAs showed, that 34% of PKs up-regulates, and less than 6% of PKs downregulate human ovarian granulosa cell apoptosis (Sirotkin et al, 2009). The involvement of PKA, PKG, MAPKs, PI3K, CDKs, TKs, and AK in control ovarian follicular cell apoptosis was shown by studies of effect of regulators of these PKs (Sirotkin et Fig.…”

Section: Protein Kinases Control Ovarian Cell Apoptosismentioning

confidence: 96%

“…Furthermore, observations of effects of activators and blockers of PKs indicate presence and importance of a number of other PKs in control of ovarian functions and in mediating effect of hormones on these functions (see below). For example, blockade of 88 PKs by siRNA constructs altered ovarian cell functions (Sirotkin et al, 2009(Sirotkin et al, , 2010. Presence of PKA and CDK/p34 in ovarian follicles is illustrated in Figure 1.…”

Section: Presence Of Protein Kinases In the Ovarymentioning

confidence: 98%

“…Genome-wide screen of PKs, which blockade by siRNAs affected human granulosa cell proliferation showed, that 36% of PKs is involved in stimulation, but only 8% of PKs in inhibition of ovarian follicular cell cycle (Sirotkin et al, 2009;Fig. 4).…”

Section: Protein Kinases Control Ovarian Cell Proliferationmentioning

confidence: 99%

See 2 more Smart Citations

Protein kinases and ovarian functions

Sirotkin

Makarevich

Grosmann³

2010

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

The present focus survey represents a short review of current knowledge concerning involvement of protein kinases in control of basic ovarian functions. Ovarian cells produce a number of protein kinases, whose expression depends on type of cells, their state and action of hormones and other protein kinases. A number of protein kinases are involved in control of ovarian cell proliferation, apoptosis, oocyte maturation, hormone release, reception and response to hormones, as well as in mediating action of hormones on these ovarian functions. Complexity of interrelationships between different protein kinase-dependent signaling pathways occurs. Protein kinases and their regulators could be used for characterization, prediction and control of ovarian folliculogenesis and atresia, Corpus luteum functions, oocyte maturation, fertility, release of hormones, response of ovarian structures to hormonal regulators, as well as for treatment of some reproductive disorders. The present data demonstrate importance of protein kinases in control of basic ovarian function and potential usage of protein kinases for characterization, prediction and control of these functions.

show abstract

Section: Protein Kinases Control Ovarian Cell Apoptosismentioning

confidence: 96%

Section: Presence Of Protein Kinases In the Ovarymentioning

confidence: 98%

See 1 more Smart Citation

Protein kinases and ovarian functions

Sirotkin

Makarevich

Grosmann³

2010

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…3). Furthermore, a number of siRNAs silencing different protein kinases was able either to up-and down-regulate proliferation of ovarian granulosa cells (Sirotkin et al, 2009b). The ability of small RNAs to suppress ovarian cell cycle indicated that RNA interference could be useful tool to suppress over proliferating ovarian cancer cells.…”

Section: Rna Interference and Ovarian Cell Proliferationmentioning

confidence: 98%

“…Effect of some miRNAs on apoptotic markers are presented at Figure 4. A number of siRNAs targeting protein kinases was able either to promote or suppress the expression of apoptosis marker of ovarian granulosa cells (Sirotkin et al, 2009b). Numerous attempts have been made to use the ability of small RNAs to affect apoptosis for reducing viability of ovarian cancer cells and inducing their death.…”

Section: Rna Interference and Ovarian Cell Apoptosismentioning

confidence: 99%

RNA interference and ovarian functions

Sirotkin

2010

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

RNA interference, a recently discovered new mechanism controlling gene expression via small RNAs, was shown to be involved in characterization and control of basic ovarian cell functions. The main classes of small RNAs, as well as their expression in ovaries have been described. Furthermore, the successful application of RNA interference for study and control of basic ovarian functions (proliferation, apoptosis, secretory activity, luteogenesis, oocyte maturation, and related ovarian cell malignant transformation) and production of recombinant proteins have been demonstrated. Application of RNA interference in reproductive biology and medicine can be successful in two main areas: (1) characterization and prediction of physiological and pathological state (association between particular small RNA and physiological or pathological processes), (2) application of small RNAs for regulation of reproductive processes and treatment of reproductive disorders or their particular indexes. Problems of improvement of small RNA delivery to target ovarian cells and potent RNA interference-related approaches for treatment of ovarian disorders (especially of ovarian cancer) have been discussed.

show abstract

Late gastrointestinal toxicity after radiation for prostate cancer

Giordano

Lee

Kuo

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUND.The current study was designed to determine rates and predictors of late, lower gastrointestinal toxicity after radiation therapy in a population‐based cohort of older men with prostate cancer.METHODS.The study population consisted of men with localized or regional stage prostate cancer who were age ≥66 years and were diagnosed between 1992 and 1999 who were identified in the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database. Gastrointestinal diagnoses were ascertained through claims from 6 to 60 months after diagnosis. The relative rates of diagnoses in the radiation group versus the nonradiation group were used as a means of estimating toxicity from radiotherapy. Cox modeling was used to determine factors associated with gastrointestinal diagnoses.RESULTS.A total of 57,955 men were included, 24,130 of whom were treated with radiation therapy. Among patients with 5 years of follow‐up, the rates of gastrointestinal diagnoses were 19.4% higher in irradiated patients than among patients who did not have local therapy. Hemorrhage was the most common diagnosis, and was increased by 18.9% among patients treated with radiation (39.6% of irradiated patients vs. comparison rates of 18.2% in patients treated with radical prostatectomy and 20.7% in patients with no local therapy). Diagnostic lower endoscopies were performed in an additional 20.9% of men (32.4% of men treated with radiation vs. 12.7% of men who underwent prostatectomy). In all, 4.4% of irradiated men were hospitalized with a gastrointestinal diagnosis versus comparison rates of 3.2% among men with no local therapy. In multivariate models, increasing patient age, hormonal therapy, comorbidity, diabetes, peripheral vascular disease, and hemorrhoids were all associated with gastrointestinal diagnoses consistent with toxicity, whereas tumor stage and grade were not predictors.CONCLUSIONS.Lower gastrointestinal toxicity after radiation therapy for prostate cancer continues for at least 5 years and may be more common than previously reported. Cancer 2006. © 2006 American Cancer Society.

show abstract

Protein kinases controlling PCNA and p53 expression in human ovarian cells

Cited by 12 publications

References 53 publications

Protein kinases and ovarian functions

Protein kinases and ovarian functions

RNA interference and ovarian functions

Late gastrointestinal toxicity after radiation for prostate cancer

Contact Info

Product

Resources

About